

09/304,694

=> d his full

(FILE 'HOME' ENTERED AT 17:36:51 ON 07 MAR 2006)

FILE 'CAPLUS' ENTERED AT 17:37:01 ON 07 MAR 2006

L1 157 SEA ABB=ON PLU=ON (EMULSIONS OR SELF EMULSIF?) (P) (PVP OR
POLYVINYLPYRROLIDONE)
L2 2 SEA ABB=ON PLU=ON (EMULSIONS OR SELF EMULSIF?) (P) (PVP OR
POLYVINYLPYRROLIDONE) (P) (HYDROPHOBIC OR INSOLUBLE) (3A)
(DRUG OR ACTIVE OR THEAPEUTIC OR MEDICAMENT)
D L2 IBIB KWIC
D L2 IBIB KWIC 1-
L3 3 SEA ABB=ON PLU=ON (EMULSIONS OR SELF EMULSIF?) (P) (PVP OR
POLYVINYLPYRROLIDONE) AND (HYDROPHOBIC OR INSOLUBLE) (3A)
(DRUG OR ACTIVE OR THEAPEUTIC OR MEDICAMENT)
L4 4 SEA ABB=ON PLU=ON (EMULSIONS OR SELF EMULSIF?) (P) (PVP OR
POLYVINYLPYRROLIDONE) AND (LIOPHILIC OR HYDROPHOBIC OR
INSOLUBLE) (3A) (DRUG OR ACTIVE OR THEAPEUTIC OR MEDICAMENT)
L5 2 SEA ABB=ON PLU=ON L4 NOT L2
D L5 IBIB KWIC 1-
L6 14 SEA ABB=ON PLU=ON PVP (2A) SOLUBILIZER
L7 2 SEA ABB=ON PLU=ON L1 AND L6
D L7 IBIB KWIC 1-
L8 28 SEA ABB=ON PLU=ON (EMULSIONS OR SELF EMULSIF?) (P) (PVP OR
POLYVINYLPYRROLIDONE) AND DRUG DELIVERY
L9 4 SEA ABB=ON PLU=ON L8 AND SURFACTANT AND FATTY ACID
D L9 IBIB KWIC 1-
D L8 IBIB KWIC 1-
L10 7 SEA ABB=ON PLU=ON L8 AND CAPSULE
L11 0 SEA ABB=ON PLU=ON L8 AND CAPSULE AND TABLET
L12 2 SEA ABB=ON PLU=ON L8 AND CAPSULE AND TABLET
L13 4 SEA ABB=ON PLU=ON L8 AND TABLET
D L10 IBIB KWIC 1-

FILE HOME

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Ma

L10 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:193985 CAPLUS

DOCUMENT NUMBER: 130:227750

TITLE: Self-emulsifiable semi-solid **capsules** with matrix system having prolonged action

INVENTOR(S): Sereno Guerra, Antonio

PATENT ASSIGNEE(S): SMB Technology, Belg.

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9912528	A1	19990318	WO 1998-BE132	19980908
W: CA, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
BE 1011363	A3	19990803	BE 1997-742	19970911
PRIORITY APPLN. INFO.:			BE 1997-742	A 19970911
REFERENCE COUNT: 3		THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

TI Self-emulsifiable semi-solid **capsules** with matrix system having prolonged action

AB A matrix self-emulsifiable semi-solid **capsule** with a matrix system having prolonged action, comprises an active principle, at least a surfactant capable of self-emulsification in an aqueous or physiol. medium in the presence of the active principle, of HLB value ranging between 1 and 20 and at least one hydrophilic organic polymer for forming a hydrophilic matrix system non-ionizable in the presence of said liquid mixture, wherein the hydrophilic organic polymer is a hydroxyethyl cellulose or hydroxypropyl cellulose with mol. weight less than 1,000,000 and preferably between 80,000 and 800,000. A **capsule** contained fenofibrate (I) 200, Gelucire 44/14 300, Klucel XHF 100, and peg 60 mg. The amount of I released over 6 h period was .apprx. 100%.

ST sustained release pharmaceutical **capsule** surfactant polymer; Klucel XHF fenofibrate sustained release **capsule**

IT **Drug delivery** systems
(**capsules**, sustained-release; self-emulsifiable semi-solid **capsules** with matrix system having prolonged action)

IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fatty; self-emulsifiable semi-solid **capsules** with matrix system having prolonged action)

IT Vinyl compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polymers; self-emulsifiable semi-solid **capsules** with matrix system having prolonged action)

IT Anti-inflammatory agents
Anxiolytics
Fungicides
Hypolipemic agents
Surfactants
(self-emulsifiable semi-solid **capsules** with matrix system having prolonged action)

IT Acrylic polymers, biological studies
Amino acids, biological studies
Diglycerides
Fats and Glyceridic oils, biological studies

Glycerides, biological studies
 Glycols, biological studies
 Lecithins
 Monoglycerides
 Peptides, biological studies
 Polymers, biological studies
 Steroids, biological studies
 Waxes

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (self-emulsifiable semi-solid **capsules** with matrix system
 having prolonged action)

IT 56-81-5D, Glycerol, derivs. 57-50-1D, Saccharose, esters 58-55-9,
 Theophylline, biological studies 9003-39-8, **Pvp** 9004-62-0,
 Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 13311-84-7,
 Flutamide 21829-25-4, Nifedipine 31329-57-4 33069-62-4, Taxol
 52806-53-8, Hydroxyflutamide 59277-89-3, Acyclovir 62571-86-2,
 Captopril 65277-42-1, Ketoconazole 79217-60-0, Cyclosporin
 121548-04-7, Gelucire 44/14 121548-05-8, Gelucire 50/13

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**self-emulsifiable** semi-solid **capsules**
 with matrix system having prolonged action)

L10 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:270790 CAPLUS

DOCUMENT NUMBER: 131:49331

TITLE: Emulsion type new vehicle for soft gelatin **capsule** available for preclinical and clinical trials: effects of PEG 6000 and PVP K30 on physicochemical stability of new vehicle

AUTHOR(S): Amemiya, Tohru; Mizuno, Satoshi; Yuasa, Hiroaki; Watanabe, Jun

CORPORATE SOURCE: Research & Development Section, Kakegawa Factory, Kakegawa, 436-0341, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1999), 47(4), 492-497

CODEN: CPBTAL; ISSN: 0009-2363

PUBLISHER: Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Emulsion type new vehicle for soft gelatin **capsule** available for preclinical and clinical trials: effects of PEG 6000 and PVP K30 on physicochemical stability of new vehicleAB To prevent temperature-dependent gel-sol transformation of an o/w emulsion type new vehicle system for a soft gelatin **capsule**, which may be available for both preclin. and clin. trials, the basic new vehicle formulation [PEG 400-purified water-medium chain triglyceride-PEG cetyl ether (77:10:10:3)] was modified by partially (1, 2 or 3%) replacing PEG 400 with PEG 6000 or PVP K30. When 2 or 3% of PEG 400 was replaced with PEG 6000, temperature-dependent gel-sol transformation was prevented at temps. below 40°, and the vehicle appeared to be stable during 8 wk of storage at 4 to 40°; the particle size distribution remained unchanged. When 1% of PEG 400 was replaced with PEG 6000, gel-sol transformation was not prevented, though phase separation was not observed at

sol state, and the particle size distribution was shifted to be in a larger particle size range after 2 wk of storage. When PEG 400 was partially (1, 2 or 3%) replaced with PVP K30, temperature-dependent gel-sol transformation

was not prevented and, after 2 wk of storage at 40°, the particle size distributions of the vehicles were shifted to be in a larger particle size range and the vehicles were separated into 2 layers. Thus, a small amount of PEG 6000 plays an important role in preventing temperature-dependent gel-sol transformation of this developed vehicle system.

ST PEG stability emulsion gelatin **capsule**; PVP stability emulsion gelatin **capsule**

IT Glycerides, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(C8-10; PEG and PVP effect on stability of emulsion vehicle for soft gelatin **capsules** for clin. trials)

IT Particle size distribution

Sol-gel transition

Viscosity

(PEG and PVP effect on stability of emulsion vehicle for soft gelatin **capsules** for clin. trials)

IT Gelatins, biological studies

Polyoxyalkylenes, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(PEG and PVP effect on stability of emulsion vehicle for soft gelatin **capsules** for clin. trials)

IT Drug delivery systems

(capsules; PEG and PVP effect on stability of emulsion

09/304,694

vehicle for soft gelatin **capsules** for clin. trials)
IT **Drug delivery** systems
(**emulsions**; PEG and **PVP** effect on stability of
emulsion vehicle for soft gelatin **capsules** for clin. trials)
IT 9003-39-8, PVP 25322-68-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PEG and PVP effect on stability of emulsion vehicle for soft gelatin
capsules for clin. trials)